NEW YORK (GenomeWeb News) – Vermillion said in a US Securities and Exchange Commission filing released after the close of the market yesterday that its shareholders elected Robert Goggin to the company's board of directors at the firm's annual meeting last week.

Goggin, who was put forth as a candidate by a trio of dissident shareholders comprising himself, Gregory Novak, and George Bessenyei, defeated Vermillion's candidate, Roberta Della Vedova, with 4,749,042 votes cast for Goggin compared to 3,938,399 for Vedova.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.

Oct
10
Sponsored by
Philips Genomics

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.